Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00483301 · ClinicalTrials.gov registry record · Phase 2
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
A Phase 2 study, sponsored by Mt. Sinai Medical Center, Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00483301 is a Phase 2 study that has completed, run by Mt. Sinai Medical Center, Miami. The registered enrollment target is 34 participants.
The verdict
NCT00483301, a Phase 2 study, has completed, sponsored by Mt. Sinai Medical Center, Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.
Interventions
- DRUG Sorafenib (BAY 43-9006)
- DRUG ABI-007(Abraxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00483301
The ClinicalTrials.gov registry entry for NCT00483301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mt. Sinai Medical Center, Miami, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib (BAY 43-9006) is the first listed.
NCT00483301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00483301 about?
NCT00483301 is a clinical study titled "A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma". The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.
What is the current status of trial NCT00483301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2007-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00483301?
The interventions under investigation include: Sorafenib (BAY 43-9006) (DRUG), ABI-007(Abraxane) (DRUG).
Who is sponsoring clinical trial NCT00483301?
This trial is sponsored by Mt. Sinai Medical Center, Miami, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.